The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence

McIntyre, Roger S.; Rodrigues, Nelson B.; Lee, Yena; Lipsitz, Orly; Subramaniapillai, Mehala; Gill, Hartej; Nasri, Flora; Majeed, Amna; Lui, Leanna M.W.; Senyk, Olena; Phan, Lee; Carvalho, Isabelle P.; Siegel, Ashley; Mansur, Rodrigo B.; Brietzke, Elisa; Kratiuk, Kevin; Arekapudi, Anil; Abrishami, Amir; Chau, Edmond; Szpejda, Witold; Rosenblat, Joshua D.

doi:10.1016/j.jad.2020.05.088

Cited by 84 publications

(63 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This report is a post hoc analysis of data previously described elsewhere (McIntyre et al, 2020). All individuals reported in this retrospective analysis herein were patients receiving care at the Canadian Rapid Treatment Center of Excellence (CRTCE) in Mississauga, Ontario, Canada.…”

Section: Methodsmentioning

confidence: 99%

The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: Individuals meeting criteria for treatment-resistant depression (TRD) are differentially affected by high levels of anxiety symptoms. Aims: There is a need to identify the efficacy of novel rapid-onset treatments in adults with mood disorders and comorbid anxious-distress. Methods: This study included patients with treatment-resistant major depressive disorder (MDD) or bipolar disorder (BD) who were receiving intravenous (IV) ketamine treatment at a community-based clinic.Anxious-distress was proxied using items from the Quick Inventory of Depressive Symptomatology–Self Report 16-item (QIDS-SR16) and Generalized Anxiety Disorder 7-item (GAD7) scales. The difference in QIDS-SR16 total score, QIDS-SR16 suicidal ideation (SI) item and GAD7 score were analyzed between groups. Results: A total of 209 adults with MDD ( n = 177) and BD ( n = 26) were included in this analysis. From this sample, 94 patients (mean = 45 ± 13.9 years) met the criteria for anxious-distress. Individuals meeting the criteria for anxious-distress exhibited a significantly greater reduction in QIDS-SR16 total score following four infusions ( p = 0.02) when compared with patients not meeting the anxious-distress criteria. Both anxious-distressed and low-anxiety patients exhibited a significant reduction in SI ( p < 0.0001) following four infusions.Finally, there was a significantly greater reduction in anxiety symptoms in the anxious-distress group compared with the non–anxious distress group following three ( p = 0.02) and four infusions ( p < 0.001). Conclusion: Patients with TRD and prominent anxiety receiving IV ketamine exhibited a significant reduction in depressive, SI and anxiety symptoms.

show abstract

Section: Methodsmentioning

confidence: 99%

The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…The authors observed rapid antidepressive and antisuicidal effects. 24 The authors of the mentioned studies did not observe any significant side effects. It remains unclear as to how repeated ketamine infusions may affect the severity of subsequent episodes of bipolar depression.…”

Section: Multiple Administrationmentioning

confidence: 89%

<p>Ketamine in Bipolar Disorder: A Review</p>

Wilkowska¹,

Szałach²,

Cubała³

2020

NDT

View full text Add to dashboard Cite

Bipolar disorder (BD) is a psychiatric illness associated with high morbidity, mortality and suicide rate. It has neuroprogressive course and a high rate of treatment resistance. Hence, there is an unquestionable need for new BD treatment strategies. Ketamine appears to have rapid antidepressive and antisuicidal effects. Since most of the available studies concern unipolar depression, here we present a novel insight arguing that ketamine might be a promising treatment for bipolar disorder.

show abstract

“…This review has shown that ketamine can make a genuine leap forward in the therapy of depression. Its clear effectiveness in reducing symptoms of depression and suicidal ideation, either after a single administration, or especially when administered repeatedly in addition to another antidepressant, is an extremely promising factor in the treatment of depression (Wilkinson et al, 2018;McIntyre et al, 2020). Furthermore, research on new molecules designed to reproduce the rapid and sustained antidepressant effects of ketamine, without its adverse effects, allows us to assume that a new era in the pharmacology of antidepressants has already begun (Chaki, 2017).…”

Section: Discussionmentioning

confidence: 99%

“…The preclinical studies on the possible use of ketamine in the therapy of depression have been mainly based on animal models of depression that have been validated over the years, through the use of classic antidepressants (Czéh et al, 2016;Planchez et al, 2019). Although the mechanism of action of ketamine (Zanos and Gould, 2018;Deyama and Duman, 2020;McIntyre et al, 2020) differs substantially from that of standard antidepressants (Feighner, 1999;Patel et al, 2017), it might be hypothesized that they share common target areas that therefore could be involved in the etiology of depression. This hypothesis might be considered to explain the antidepressant effect produced by selective serotonin reuptake inhibitor (SSRIs), and by selective norepinephrine reuptake inhibitor (SNRI), which, although acting on two different transmission systems, can produce equivalent antidepressant effects (Artigas, 2015;Gałecki et al, 2018;Wagner et al, 2018).…”

Section: Role Of Bnst In the Antidepressant Effect Of Ketamine And Standard Antidepressantsmentioning

confidence: 99%

Repurposing Ketamine in Depression and Related Disorders: Can This Enigmatic Drug Achieve Success?

et al. 2021

View full text Add to dashboard Cite

Repurposing ketamine in the therapy of depression could well represent a breakthrough in understanding the etiology of depression. Ketamine was originally used as an anesthetic drug and later its use was extended to other therapeutic applications such as analgesia and the treatment of addiction. At the same time, the abuse of ketamine as a recreational drug has generated a concern for its psychotropic and potential long-term effects; nevertheless, its use as a fast acting antidepressant in treatment-resistant patients has boosted the interest in the mechanism of action both in psychiatry and in the wider area of neuroscience. This article provides a comprehensive overview of the actions of ketamine and intends to cover: (i) the evaluation of its clinical use in the treatment of depression and suicidal behavior; (ii) the potential use of ketamine in pediatrics; (iii) a description of its mechanism of action; (iv) the involvement of specific brain areas in producing antidepressant effects; (v) the potential interaction of ketamine with the hypothalamic-pituitary-adrenal axis; (vi) the effect of ketamine on neuronal transmission in the bed nucleus of stria terminalis and on its output; (vii) the evaluation of any gender-dependent effects of ketamine; (viii) the interaction of ketamine with the inflammatory processes involved in depression; (ix) the evaluation of the effects observed with single or repeated administration; (x) a description of any adverse or cognitive effects and its abuse potential. Finally, this review attempts to assess whether ketamine’s use in depression can improve our knowledge of the etiopathology of depression and whether its therapeutic effect can be considered an actual cure for depression rather than a therapy merely aimed to control the symptoms of depression.

show abstract

The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence

Cited by 84 publications

References 36 publications

The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence

The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence

<p>Ketamine in Bipolar Disorder: A Review</p>

Repurposing Ketamine in Depression and Related Disorders: Can This Enigmatic Drug Achieve Success?

Contact Info

Product

Resources

About